Cell Therapeutics, Inc. (NASDAQ (GM): CTIC)
Seattle, WA 98119 (Map) Phone: 206-282-7100
Fax: 206-284-6206
Toll Free: 800-215-2355
http://www.cticseattle.com
Overview
Cell Therapeutics (CTI) is a toxic avenger. The firm creates more effective and less toxic treatments for various forms of cancer. CTI is also developing a number of other cancer-fighting compounds, including paclitaxel poliglumex (Opaxio, formerly branded as Xyotax) for non-small cell lung and ovarian cancers, and pixantrone, another treatment for non-Hodgkin's lymphoma. The company's Systems Medicine subsidiary is working on a potential sarcoma-fighter called brostallicin. It no longer markets any commercial products and instead focuses on research and development projects.
Sample OverviewKey Numbers from Hoover's UK
Key financials for Cell Therapeutics, Inc. (NASDAQ (GM): CTIC)
| Company Type | Public (NASDAQ (GM): CTIC) |
|---|---|
| Fiscal Year-End | December |
| 2008 Sales (mil.) | £7.9 |
| 1-Year Sales Growth | 8,901.6% |
| 2008 Net Income (mil.) | (£124.3) |
| 2008 Employees | 194 |
| 1-Year Employee Growth | (15.7%) |
Key People from Hoover's UK
Key people and executives for Cell Therapeutics, Inc. (NASDAQ (GM): CTIC)
| Chairman | Phillip M. (Phil) Nudelman (Subscribers see complete biographies -- view sample)
Connect to this executive |
|---|---|
| CEO and Director | James A. Bianco Connect to this executive |
| EVP Finance and Administration | Louis A. Bianco Connect to this executive |
Top Competitors from Hoover's UK
Top competitors of Cell Therapeutics, Inc. (NASDAQ (GM): CTIC)
There are 19 competitors for Cell Therapeutics; see more.
